| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | CEO
2 companies
Uli Hacksell last filed a Form 4 in March 2020, as CEO at ACAD. The filings on record cover 2 companies. Uli Hacksell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 115,549 shares of ACAD. The ACAD filings lean toward selling, a net 60,000 shares.
Uli Hacksell has 14 Form 4 filings on record from January 2015 to March 2020, across 2 companies: Director at Avalo Therapeutics (AVTX), 2015–2020; CEO at Acadia Pharmaceuticals (ACAD), 2015.
The 22 reported transactions were 12 option or other derivative awards, 4 gifts, 2 open-market purchases and 2 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $15K and 2 sales worth about $2.0M.
The only open-market purchase was 20,000 shares of AVTX at an average $0.74 on June 9, 2017, about $15K.
The largest open-market sale was 30,000 shares of ACAD at an average $34.30 on February 17, 2015, about $1.0M.
Shares as reported in the last Form 4 for each company; the most recent is from March 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.